On September 8, the 25th China International Fair for Investment & Trade (CIFIT) grandly opened in Xiamen. Ms Theresa Tse, Chairwoman of the Board of Sino Biopharm (1177.HK), was invited to attend and shared her views on international cooperation, innovation opportunities, and future challenges in the pharmaceutical industry during the roundtable forum "Dialogue between Renowned Private Enterprises and the Fortune Global 500".

As China's only national-level major exhibition themed on promoting two-way investment, the 2025 CIFIT attracted delegations from over 120 countries and regions and 11 international organizations. CIFIT closely followed the annual theme of "Joining Hands with China, Investing in the Future", and focused on three major sections: "Investing in China", "China Investment", and "International Investment", sending a positive signal of China's commitment to advancing high-level opening-up.

During the roundtable session that afternoon, Ms Theresa Tse pointed out that business development collaborations between Chinese innovative drug companies and international pharmaceutical firms are becoming increasingly frequent, with the value and number of license-out deals continuously rising. In 2024, the number of overseas deals by Chinese pharmaceutical companies was nearly 100, with a total value exceeding $59 billion. In the first half of this year, the number of overseas deals by Chinese pharmaceutical companies has already surpassed 70, the highest in the past 5 years, with a total value exceeding $60 billion, demonstrating the strong momentum of China's pharmaceutical innovation and its increasing internationalization.

She further emphasized that China has become one of the world's important sources of innovation, attracting global attention. Currently, 3 out of every 10 innovative drugs in development globally come from Chinese laboratories. Among the clinical trials registered throughout the year, Class 1 innovative drugs account for 68.3%. Compared to the starting point in 2015 when China's R&D pipeline accounted for only 4% of the global total, Chinese innovative drugs have achieved a quantum leap. This growth is not only reflected in numbers but also profoundly in the transformation of the industrial landscape and R&D models.

MsTheresa Tse frankly stated, "We must clearly recognize that the journey from "New in China" to "New Globally" still requires climbing a steep and difficult slope."Recently, Sino Biopharm's $1 billion acquisition of the star biotech company LaNova Medicines was precisely to rapidly deploy next-generation tumor immunotherapy technologies and further enhance global competitiveness. She believes that tackling major diseases such as tumors, autoimmune disorders, and CNS disorders is the core direction of pharmaceutical innovation, and the integration of cross-disciplinary technologies like artificial intelligence, new materials, and nanorobots will bring revolutionary breakthroughs to the industry.

"There is no ceiling in the field of life and health." Ms Theresa Tse stated that Sino Biopharm will continue to increase its investment in innovative R&D. She quoted the phrase "appreciate each other's beauty, and share the beauty together", calling on Chinese and foreign enterprises to discover each other's strengths and maintain their own characteristics in cooperation, to achieve win-win results through complementary advantages, jointly maintain the stability of the global industrial chain, and let more innovative achievements benefit patients worldwide.

Declaration:

The copyright of this article is owned by the original author or our company. Unauthorized use by means of reprinting, copying, filming, adapting, or compiling is prohibited. The portrait rights of the individuals appearing in this article belong to the individuals themselves. Unauthorized use is prohibited.